Duramed has initiated patent litigation in the US District Court of New Jersey seeking injunctive relief.
Bruce Downey, chairman and CEO of Barr, said: “We believe that Watson’s product should be removed from the market, and that the company is due monetary compensation from Watson. In addition, we intend to protect our intellectual property from potential generic competition by Sandoz while our patent is in force.”